Sponsored

Imugene releases new update on Phase 1 clinical trial of PD1-Vaxx

Highlights 

  • Imugene Limited (ASX:IMU) has released a Phase 1 clinical trial update of PD1-Vaxx.
  • The Company is continuing with a Phase 1 dose escalation trial of PD1-Vaxx, which is recruiting patients with NSCLC.
  • Imugene informed that three patients have now started their dosing schedule for the third monotherapy cohort of the Phase 1 trial.

Australia-based Imugene Limited (ASX:IMU) has recently released a Phase 1 clinical trial update of its B-cell immunotherapy PD1-Vaxx. Imugene’s PD1-Vaxx immunotherapy approach has been designed to target lung cancer tumours by interfering with PD-L1/PD-1 binding and interaction and produce an anticancer attack akin to what Opdivo® and Keytruda® offer in this revolutionary treatment of a range of cancers.

As per Imugene, PD1-Vaxx has been discovered to tackle an unmet need. Although PD-1 inhibitors Keytruda® and Opdivo® have shown remarkable clinical success in some patients, some 60-70 per cent of patients receiving anti-PD-1 monotherapy treatments remain resistant to these therapies and do not respond.

PD-1 Vaxx is a selective, mechanism-based, targeted therapy using peptide-based B-Cell epitopes and peptide immuno-therapeutics that block the growth and spread of cancers by inhibiting oncogenic signalling pathways.

Must Read: Imugene Ticks Off a Key Milestone in PD1-Vaxx Phase 1 Trial, Shares Up

The Company is continuing with a Phase 1 dose escalation trial of PD1-Vaxx, which is recruiting patients with NSCLC (non-small cell lung cancer).

What does the latest update say?

Imugene informed that three patients have now started their dosing schedule for the third monotherapy cohort of Phase 1 PD1-Vaxx trial. Barring any unexpected clinical observations, the Company expects the optimal biological dose of 100µg to be ratified at the next Cohort Review Committee (CRC). The next CRC is presently scheduled for the first week of October.

The Company further notified that the clinical results continue to suggest that PD1-Vaxx is demonstrating early signs of an immune response in lung cancer patients. Meanwhile, the antibodies to the target biomarker PD-1 are also apparent in validated assays.

Related Read: Imugene Limited (ASX:IMU) Doses First Patient in Cohort 2 under PD1-Vaxx Phase 1 Trial

Market opportunities in PD-1 space

Currently, the PD-1 space is a thriving market for checkpoint inhibitors. Since the US regulator FDA’s approval of the first PD-1 checkpoint inhibitor drug Keytruda® in 2014, there has been a significant increase in the number of these drugs being developed. At present, over 1500 clinical trials testing checkpoint inhibitors are continuing, as estimated by the Cancer Research Institute.

In its December 2020 newsletter, Imugene highlighted that the global immune checkpoint inhibitors market is expected to cross US$25 billion by 2022 (as per RNCOS 2018 report). Moreover, the checkpoint inhibitors are likely to account for a major percentage of total cancer immunotherapy revenue within 10 years.

As of 3:54 PM AEST, Imugene shares are trading at AU$0.345, with a rise of about 1.5 per cent.

Do Not Miss: Imugene Limited (ASX:IMU) Progressing with PD1-Vaxx Phase I Trial

Comment


Disclaimer

Ad

GET A FREE STOCK REPORT


Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.


   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK